Varicella-Zoster Virus Antibodies, IgG and IgM
Also known as: VZV PAN
Use
This test aids in diagnosing acute Varicella-Zoster infections and detecting past exposure or vaccination. It measures the presence of IgG and IgM antibodies to determine if an individual has a current infection, has been exposed in the past, or has been vaccinated against the virus. Varicella-Zoster Virus, also known as Herpes Zoster or VZV, can cause chickenpox upon primary infection and shingles upon reactivation. Identification of the IgM antibody indicates a current or recent infection, while the presence of the IgG antibody could indicate either a past infection or vaccination.
Special Instructions
Not provided.
Limitations
The semi-quantitative nature of this test means it may not definitively distinguish between past and acute infections, especially in cases where low levels of IgM antibodies persist for more than 12 months post-infection or immunization. Repeat testing is suggested for equivocal IgM levels between 0.91 and 1.09 ISR. The test's sensitivity and specificity should also be considered when interpreting results.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 5403-1 - VZV IgG Ser IA-aCnc
- 5404-9 - VZV IgM Ser IA-aCnc
- 5403-1 - VZV IgG Ser IA-aCnc
- 5404-9 - VZV IgM Ser IA-aCnc
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.2 mL
Container
ARUP standard transport tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection.
Causes for Rejection
Undisclosed issues at individual component level.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year |
Other tests from different labs that may be relevant